Why the study?
Data regarding the longer-term durability of transcatheter heart valves are scarce.
Does the Portico transcatheter heart valve system provide durable clinical outcomes and hemodynamic performance at 5 years in patients at high or extreme surgical risk?
Does the Portico transcatheter heart valve system provide durable clinical outcomes and hemodynamic performance at 5 years in patients at high or extreme surgical risk?
The Portico self-expanding transcatheter heart valve demonstrates favorable 5-year durability and clinical outcomes with low rates of bioprosthetic valve failure in high-risk surgical patients.
Supports Portico THV durability in high-risk patients; extends 5-year bioprosthetic valve evidence beyond shorter follow-up.
BACKGROUND: There is a paucity of data regarding the longer-term durability of transcatheter heart valves. This analysis aimed to describe the 5-year clinical outcomes and valve durability for patients treated with the Portico transcatheter heart valves across 3 studies harmonized in their prospective enrollment, inclusion/exclusion criteria, centralized independent core laboratory echocardiographic analysis, and independent clinical events committee adjudication. METHODS: Patient-level data from the PORTICO IDE randomized controlled trial, the PORTICO I postmarket study, and the PORTICO continued access protocol were pooled using a random-effects meta-analysis model. All 3 studies collected follow-up data at discharge, 30 days, and annually through 5 years. Adverse events and pooled echocardiographic data were assessed using Valve Academic Research Consortium-2 definitions. Durability definitions were adapted from Valve Academic Research Consortium-3 and European Association of Percutaneous Cardiovascular Interventions/European Society of Cardiology/European Association for Cardio-Thoracic Surgery consensus guidelines. The 5-year bioprosthetic valve failure rate was 2.7%, including a 0.7% valve-related death rate and a 2.0% valve reintervention rate, but no patients with severe hemodynamic structural valve deterioration. Moderate hemodynamic structural valve deterioration occurred in 0.9% of the patients at 5 years. Hemodynamic performance and transcatheter heart valve durability remained stable irrespective of annular size. CONCLUSIONS: The use of the Portico transcatheter heart valve system in patients at high or extreme surgical risk demonstrated favorable clinical outcomes and hemodynamic performance with low transvalvular gradients and greater than mild paravalvular leak. Furthermore, bioprosthetic valve failure rates were low with no incidence of severe hemodynamic structural valve deterioration at 5 years, irrespective of annular size. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02000115 and NCT01802788.
No takes yet. Share an insight, caveat, or question.
Puri et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: